ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Bought by Silverarc Capital Management LLC

Silverarc Capital Management LLC raised its holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,178,300 shares of the company's stock after acquiring an additional 78,810 shares during the period. ORIC Pharmaceuticals makes up approximately 2.1% of Silverarc Capital Management LLC's investment portfolio, making the stock its 17th largest position. Silverarc Capital Management LLC owned about 1.67% of ORIC Pharmaceuticals worth $9,509,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of ORIC. KLP Kapitalforvaltning AS acquired a new stake in shares of ORIC Pharmaceuticals in the fourth quarter valued at approximately $50,000. PNC Financial Services Group Inc. raised its holdings in shares of ORIC Pharmaceuticals by 22.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock worth $109,000 after acquiring an additional 2,520 shares during the period. Tower Research Capital LLC TRC raised its stake in ORIC Pharmaceuticals by 1,048.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 14,661 shares of the company's stock worth $118,000 after purchasing an additional 13,384 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in ORIC Pharmaceuticals by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,963 shares of the company's stock valued at $121,000 after purchasing an additional 1,395 shares during the last quarter. Finally, ExodusPoint Capital Management LP purchased a new stake in shares of ORIC Pharmaceuticals in the 4th quarter valued at approximately $189,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Guggenheim restated a "buy" rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright reissued a "buy" rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a research note on Friday, February 21st. Wedbush restated an "outperform" rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. JPMorgan Chase & Co. lifted their price objective on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, ORIC Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $18.86.

ORIC Pharmaceuticals Trading Down 1.7 %

Shares of ORIC stock traded down $0.09 on Friday, reaching $5.10. 362,897 shares of the stock were exchanged, compared to its average volume of 635,470. The company has a market capitalization of $362.24 million, a price-to-earnings ratio of -2.80 and a beta of 1.38. The business's 50 day moving average price is $6.39 and its 200 day moving average price is $8.34. ORIC Pharmaceuticals, Inc. has a twelve month low of $3.90 and a twelve month high of $14.67.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.01. Equities research analysts forecast that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.